CNQX disodium salt

  Cat. No.:  DC10671   Featured
Chemical Structure
479347-85-8
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
CNQX is a potent AMPA/kainate receptor antagonist. Also antagonist at glycine modulatory site on NMDA receptor complex.
Cas No.: 479347-85-8
Chemical Name: CNQX disodium salt
Synonyms: CNQX disodium salt
SMILES: [Na+].[Na+].N#CC1=CC2=NC(=C(N=C2C=C1[N+]([O-])=O)[O-])[O-]
Formula: C9N4O4Na2H2
M.Wt: 276.1161
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
In Vivo: CNQX disodium (FG9065 disodium; 0.75-3 mg/kg; IP; 20 min before testing) decreased the number of cocaine responses in a dose-dependent manner during the first 15-min cocaine-free interval[4]. The bilateral infusion of CNQX disodium (0.5 or 1.25 μg) into the amygdala or dorsal hippocampus 10 min prior to a retention test partially blocks the expression of stepdown inhibitory avoidance in rats 24 h after training. CNQX disodium causes a complete blockade at a dose of 0.5 μg[5]. Animal Model: Male Wistar rats weighing 180-200 g[4] Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval.
In Vitro: CNQX disodium (FG9065 disodium; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices[2]. CNQX disodium (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments[3].
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC8824 Traxoprodil Traxoprodil is an NMDA ε 2 (NR2B) antagonist that has been studied as an alternative to serotonin selective reuptake inhibitors.
DC7863 Talampanel (GYKI 53773) Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor.
DC8175 Rapastinel(GLYX-13) Rapastinel(GLYX-13) is a NMDA receptor partial agonist that acts at the glycine site.
DC8307 QNZ46 QNZ is a NR2C/NR2D-selective NMDA receptor non-competitive antagonist (IC50 values are 3, 6, 229, and >300, >300 μM for NR2D, NR2C, NR2A, NR2B, and GluR1, respectively).
DC7226 Perampanel(E2007) Perampanel(E2007; ER 155055-90) is a selective noncompetitive AMPA-type glutamate receptor antagonist which has demonstrated anticonvulsant activity in experimental seizure models and antiepileptic activity in clinical trials.
DC7989 PEPA PEPA is an allosteric modulator of AMPA receptors; binds to the GluA2o and GluA3o LBDs and can be utilized as an indicator of AMPA receptor heterogeneity.
DC11382 NYX-2925 NYX-2925 is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory.
DC7576 NVP-AAM077 NVP-AAM077 is a potent antagonist for NMDA receptors.
DC11406 NBQX NBQX is a potent aminomethylphosphonic acid receptor (AMPAR) antagonist with an IC50 of 0.7 ± 0.1 μM.
DC7194 MDL 29951 MDL-29951 is a novel glycine antagonist of NMDA receptor activation (Ki=0.14 mM, [3H]glycine binding) in vitro and in vivo.
X